[ET Net News Agency, 1 December 2023] HSBC initiates coverage of Giant Biogene (02367)
with a target price of HKD47.5 and a "buy" rating.
The research house said it has done a scenario analysis of potential earnings growth and
valuation based on the performance of the company's listed peers in China in terms of
market share, margins and distribution channels. This work shows that the downside/upside
to its current share price is between -19% and +77%. This is a wide range, and it
concludes that Giant Biogene will land somewhere in the middle. (RC)